Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1050 Waltham Street, Suite 302 LEXINGTON MA 02421 |
Tel: | 1-617-2219100 |
Website: | https://www.kerostx.com |
IR: | See website |
Key People | ||
Jasbir Seehra Chief Executive Officer, Director | Keith C. Regnante Chief Financial Officer | Christopher R. Rovaldi Chief Operating Officer |
Business Overview |
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis. |
Financial Overview |
For the fiscal year ended 31 December 2023, Keros Therapeutics Inc revenues increased from $0K to $151K. Net loss increased 46% to $153M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 16% to $91.9M (expense), Stock-based Compensation in R&D increase of 72% to $14.1M (expense). |
Employees: | 136 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,802M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.15M as of Dec 31, 2023 |
EBITDA (TTM): | -$169.13M as of Dec 31, 2023 |
Net annual income (TTM): | -$152.99M as of Dec 31, 2023 |
Free cash flow (TTM): | -$126.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 35,982,628 as of Feb 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |